Epigenetic Insights into Bladder Cancer: The Role of Urine DNA Methylation Assays: Mini Review

Bladder cancer remains a major global health challenge due to its high incidence, recurrence rates, and reliance on invasive diagnostic procedures. While conventional methods, such as cystoscopy and urine cytology, are considered standard, they often demonstrate limited sensitivity, particularly in detecting early-stage disease. Epigenetic alterations, particularly DNA methylation, are now recognized as critical in bladder cancer development and progression. Non-invasive urine-based DNA methylation assays have emerged as promising diagnostic and monitoring tools by detecting tumor-derived molecular changes in exfoliated DNA. Notably, hypermethylation of tumor suppressor gene promoters such as CDKN2A, RASSF1A, and DAPK, as well as hypomethylation in oncogene-associated regions like MYC and CCND1, have shown strong associations with bladder cancer presence and severity. Recent advancements in detection technologies, including methylation-specific PCR (MSP), droplet digital PCR (ddPCR), and Next-Generation Sequencing (NGS), have significantly improved sensitivity and specificity, enabling earlier diagnosis, better risk stratification, and the development of personalized management strategies. Clinical studies also point to the potential of novel markers like TWIST1, NID2, and mDMRTA2 in enhancing diagnostic accuracy. Despite these advances, broader clinical validation and standardized testing protocols are essential for integrating methylation assays into routine clinical practice. These assays represent a transformative shift toward non-invasive, accurate, and patient-centric bladder cancer care.